BioSante Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

  BioSante Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price
  Listing Requirement

Business Wire

LINCOLNSHIRE, Ill. -- June 19, 2012

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today that it has
received notice from The NASDAQ Stock Market indicating that BioSante has
regained compliance with the minimum bid price requirement for continued
inclusion of its common stock on The NASDAQ Global Market.

As previously announced by BioSante on June 11, 2012 the Company plans to
initiate two new LibiGel Phase III efficacy trials. This decision is based on
an extensive analysis of previous efficacy data, consultation with key opinion
leaders (KOLs) in female sexual dysfunction, testosterone therapy and placebo
effects, as well as a meeting with the U.S. Food and Drug Administration
(FDA). BioSante also intends to continue the on-going LibiGel Phase III
cardiovascular and breast cancer safety study as per protocol. LibiGel
(testosterone gel) is in development for the treatment of female sexual
dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in
menopausal women.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products
for female sexual health and oncology. BioSante´s products include LibiGel^®
(transdermal testosterone gel) for the treatment of female sexual dysfunction
(FSD), specifically hypoactive sexual desire disorder (HSDD), which is in
Phase III clinical development. BioSante also is developing a portfolio of
cancer vaccines, with 17 Phase I and Phase II clinical trials currently
on-going. Four of these vaccines have been granted Orphan Drug designation by
the U.S. Food and Drug Administration (FDA). BioSante´s other products include
an FDA-approved testosterone gel for male hypogonadism, which is licensed to
Teva Pharmaceuticals USA, Inc., and the Pill-Plus™, an oral contraceptive in
Phase II clinical development by Pantarhei Bioscience B.V. BioSante´s first
FDA-approved product, Elestrin™ (estradiol gel) indicated for the treatment of
hot flashes associated with menopause, is marketed in the U.S. by Jazz
Pharmaceuticals, BioSante´s licensee. Additional information is available
online at: www.biosantepharma.com.

Forward-Looking Statements

To the extent any statements made in this release deal with information that
is not historical, these are forward-looking statements under the Private
Securities Litigation Reform Act of 1995. Such statements include, but are not
limited to, statements about the continued listing of BioSante’s common stock
on The NASDAQ Global Marketand other statements identified by words such as
“plans," "intends," "may," "could," other words of similar meaning,
derivations of such words and the use of future dates. Forward-looking
statements by their nature address matters that are, to different degrees,
uncertain. Uncertainties and risks may cause BioSante´s actual results to be
materially different than those expressed in or implied by BioSante´s
forward-looking statements. For BioSante, particular uncertainties and risks
include, among others, risks and uncertainties related to the market price of
BioSante’s securities and its continued listing on The NASDAQ Global Market,
uncertainties regarding clinical testing, the difficulty of developing
pharmaceutical products, obtaining regulatory and other approvals and
achieving market acceptance; the marketing and other success of BioSante´s
licensees or sublicensees and BioSante´s future revenues, if any, from its
licensees and sublicensees; uncertainties relating to the future and costs of
BioSante´s product development programs and BioSante´s need for and ability to
obtain additional financing if needed. More detailed information on these and
additional factors that could affect BioSante´s actual results are described
in BioSante´s filings with the Securities and Exchange Commission, including
its most recent annual report on Form 10-K and subsequent quarterly report on
Form 10-Q. All forward-looking statements in this release speak only as of the
date of this release and are based on BioSante´s current beliefs and
expectations. BioSante undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information, future
events or otherwise.

Contact:

For Investors:
The Trout Group LLC
Tricia Swanson, (646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary, 312-506-5220
azachary@harrisdmckinney.com
 
Press spacebar to pause and continue. Press esc to stop.